KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Total Liabilities: 2009-2024

Historic Total Liabilities for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $2.2 billion.

  • Novavax's Total Liabilities fell 40.30% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 40.30%. This contributed to the annual value of $2.2 billion for FY2024, which is 13.13% down from last year.
  • Novavax's Total Liabilities amounted to $2.2 billion in FY2024, which was down 13.13% from $2.5 billion recorded in FY2023.
  • Over the past 5 years, Novavax's Total Liabilities peaked at $2.9 billion during FY2021, and registered a low of $955.3 million during FY2020.
  • In the last 3 years, Novavax's Total Liabilities had a median value of $2.5 billion in 2023 and averaged $2.5 billion.
  • As far as peak fluctuations go, Novavax's Total Liabilities skyrocketed by 206.55% in 2021, and later fell by 13.13% in 2024.
  • Yearly analysis of 5 years shows Novavax's Total Liabilities stood at $955.3 million in 2020, then spiked by 206.55% to $2.9 billion in 2021, then decreased by 1.22% to $2.9 billion in 2022, then declined by 13.08% to $2.5 billion in 2023, then declined by 13.13% to $2.2 billion in 2024.